"Strontium Radioisotopes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Unstable isotopes of strontium that decay or disintegrate spontaneously emitting radiation. Sr 80-83, 85, and 89-95 are radioactive strontium isotopes.
| Descriptor ID |
D013326
|
| MeSH Number(s) |
D01.268.552.850.500.685 D01.268.556.825.500.685 D01.496.749.815 D01.496.840.685 D01.552.539.861.500.685 D01.552.544.825.500.685
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Strontium Radioisotopes".
Below are MeSH descriptors whose meaning is more specific than "Strontium Radioisotopes".
This graph shows the total number of publications written about "Strontium Radioisotopes" by people in this website by year, and whether "Strontium Radioisotopes" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Strontium Radioisotopes" by people in Profiles.
-
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer. 2015 Jan 01; 121(1):69-76.
-
Hypocalcemia associated with strontium-89 administration in a patient with diffuse bone metastases from neuroendocrine carcinoma. J Pain Symptom Manage. 2009 May; 37(5):923-9.
-
Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005 Nov 01; 23(31):7904-10.
-
A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer. 2003 Jun 15; 97(12):2988-94.
-
Targeting prostate cancer bone metastases. Cancer. 2003 Feb 01; 97(3 Suppl):785-8.
-
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001 Feb 03; 357(9253):336-41.
-
Acute myelogenous leukemia after exposure to strontium-89 for the treatment of adenocarcinoma of the prostate. Cancer. 2000 Jul 01; 89(1):226-7.
-
Localization of megakaryocytes in normal mice and following administration of platelet antiserum, 5-fluorouracil, or radiostrontium: evidence for the site of platelet production. Exp Hematol. 1997 Jul; 25(7):638-48.
-
Calculation of the dose distribution in water from 71Ge K-shell x-rays. Phys Med Biol. 1997 Jun; 42(6):1023-32.
-
Strontium-89 for symptomatic metastatic prostate cancer to bone: recommendations for hospice patients. Hosp J. 1996; 11(2):1-10.